Kassi Filkins

Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.

A priority review in Stargardt disease, two pivotal-trial milestones, an emerging bispecific for wet AMD, and new diagnostic guidance defined a busy August for retina.

A systematic review of 21 studies found OCTA detects early diabetic retinopathy—reduced vessel density being the most consistent biomarker—but heterogeneous, unstandardized evidence isn't sufficient for routine clinical screening yet.

Angela Y. Zhu, MD, of Bascom Palmer Eye Institute, explains how to distinguish eye allergy from vision-threatening VKC and AKC in children and when steroid-sparing therapy and referral are warranted.

Kodiak fully enrolled the first pivotal cohort of its phase 3 PEAK trial testing KSI-101 for inflammatory macular edema, with topline data expected December 2026.

Dante Pieramici, MD, discusses EYP-1901, a sustained-delivery tyrosine kinase inhibitor targeting VEGF, PDGF, and IL-6 JAK/STAT signaling, in the phase 3 COMO and CAPRI diabetic macular edema trials.

Dante Pieramici, MD, breaks down the phase 3 COMO and CAPRI trials of EYP-1901 (Duravyu), an insert designed to ease treatment burden in diabetic macular edema.

Neel S. Vaidya, MD, MPH, MBA, on why keratoconus can progress aggressively in children and teens—and how early topographic screening and prompt crosslinking protect long-term vision.

Phase 3 DURAVYU insert misses key vision endpoint in wet AMD but cuts injections; pivotal LUCIA readout may decide its future.

EyePoint has finished enrolling both pivotal Phase 3 trials evaluating its sustained-release intravitreal insert against aflibercept in diabetic macular edema, setting up a topline readout in late 2027.

Noha Ekdawi, MD, FAAP, explains why pediatric myopia demands individualized, progression-based management. She details how they sequence spectacle defocus lenses, low-dose atropine, and specialty contacts; drive long-term adherence; and frame lifetime risk for parents without causing alarm.

Harrow will acquire Tyrvaya, the only FDA-approved nasal spray for dry eye disease, from Viatris for up to $100 million, complementing its cyclosporine product Vevye.

The first half of 2026 turned on inherited pediatric eye disease, with 2 gene therapy programs advancing toward registration and a high-profile complete response letter in a childhood-onset optic neuropathy.

The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.

Seven-year Vestrum data: anti-VEGF gaps hit 40% of patients with wet AMD by year 1, worsening vision.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.

Charles Wykoff, MD, PhD, of Retina Consultants of Texas, discusses 1 year of real-world revakinagene taroretcel experience, covering patient selection, surgical technique, early safety outcomes, and the platform’s potential beyond MacTel.

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

Cynthia Toth, MD, of Duke University, discusses new BabySTEPS research showing that retinal nerve fiber layer and choroidal thickness on OCT correlate with 2-year neurodevelopmental outcomes in preterm infants and what it will take to bring bedside screening into routine NICU care.

A recap of the FDA approvals, phase 3 readouts, and pipeline data that shaped diabetic eye disease care in the first half of 2026.